Literature DB >> 2249373

The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects.

D G May1, J A Porter, J P Uetrecht, G R Wilkinson, R A Branch.   

Abstract

The relative importance of N-hydroxylation and acetylation of dapsone to the oral clearance of dapsone (100 mg) was investigated in seven healthy volunteers. Plasma dapsone and monoacetyldapsone concentrations rose rapidly with subsequent similar monoexponential elimination. The oral clearance of dapsone was low (33 +/- 14 ml/min), with a threefold variability. Four subjects were identified as fast acetylators; however, differences in acetylation did not explain the variability in oral clearance. The cumulative urinary recoveries of dapsone and its hydroxylamine were approximately 20% of the dose. The formation clearance of hydroxylamine, which exhibited a tenfold intersubject variability, was closely associated with the oral clearance of dapsone (r = 0.96). Thus, the formation of the hydroxylamine is more important than acetylation in determining dapsone's intersubject variability in oral clearance. Variation in N-hydroxylation may have clinical consequences, because the hydroxylamine is considered to be important in dapsone-mediated toxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2249373     DOI: 10.1038/clpt.1990.204

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  How Clinically Relevant is Dapsone-related Peripheral Neuropathy?: An Overview of Available Data with Emphasis on Clinical Recognition.

Authors:  Morgan McCarty
Journal:  J Clin Aesthet Dermatol       Date:  2010-03

Review 2.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

3.  Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection.

Authors:  B L Lee; S Safrin; V Makrides; J G Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children.

Authors:  M Mirochnick; E Cooper; K McIntosh; J Xu; J Lindsey; D Jacobus; L Mofenson; J L Sullivan; W Dankner; L M Frenkel; S Nachman; D W Wara; D Johnson; V R Bonagura; M H Rathore; C K Cunningham; J McNamara
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 5.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

6.  Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.

Authors:  M Opravil; B Joos; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

7.  A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.

Authors:  Ashish Sharma; Sylvie Pilote; Pierre M Bélanger; Marie Arsenault; Bettina A Hamelin
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

8.  The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients.

Authors:  M D Coleman; L E Rhodes; A K Scott; J L Verbov; P S Friedmann; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 9.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.

Authors:  Jennifer L Dumouchel; Valerie M Kramlinger
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.